Latest News and Press Releases

AGOURA HILLS, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc.  (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M....

AGOURA HILLS, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation...

AGOURA HILLS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published...

AGOURA HILLS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug...

In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements...

OT-101 - a TGF-β2 antisense - has demonstrated potent antiviral activity against COVID-19   OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future...

AGOURA HILLS, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD,...

AGOURA HILLS, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided...

AGOURA HILLS, Calif. and DEERFIELD, Ill., March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI)...

OT-101- a TGF-β2 inhibitor - has demonstrated potent antiviral activity against coronavirus   OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral...